Page last updated: 2024-11-04

chloral hydrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2707
CHEMBL ID455917
CHEBI ID28142
SCHEMBL ID34327
MeSH IDM0004114

Synonyms (138)

Synonym
LS-12935
sk-chloral hydrate
sontec
somni sed
escre
nycton
rectules
nycoton
chloraldurat
2,2-trichloro-1,1-ethanediol
lycoral
kessodrate
chloral monohydrate
noctec
chloradorm
oradrate
somnos
bi 3411
felsules
phaldrone
trichloroacetaldehyde monohydrate
nsc-3210
hynos
hydral
lorinal
1,1-trichloro-2,2-dihydroxyethane
tosyl
nsc3210
trichloroacetaldehyde hydrate
dormal
1, 2,2,2-trichloro-
cohidrate
wln: qyqxggg
trawotox
trichloracetaldehyd-hydrat
chloralhydrat
CHEBI:28142 ,
somnote
aquachloral supprettes
2,2,2-trichloro-1,1-ethanediol
knockout drops
1,1,1-trichloro-2,2-dihydroxyethane
1,1,1-trichloro-2,2-ethanediol
chloralhydrate
epa pesticide chemical code 268100
trichloracetaldehyd-hydrat [german]
chloraldurat [german]
brn 1698497
nsc 3210
caswell no. 168
chloralvan
ccris 4142
nortec
chloraldural [swiss]
hydrate de chloral
aquachloral
einecs 206-117-5
chloralex
hsdb 222
trichloroacetaldehyde, hydrated
dea no. 2465
chlorali hydras
ai3-00082
ethanediol, 2,2,2-trichloro-
novochlorhydrate
kloralhydrat
2,2,2-trichloroethane-1,1-diol ,
inchi=1/c2h3cl3o2/c3-2(4,5)1(6)7/h1,6-7
1,1-ethanediol, 2,2,2-trichloro-
C06899
chloral hydrate ,
302-17-0
DB01563
NCGC00159374-02
D00265
chloral hydrate (jp17/usp)
noctec (tn)
hydrate, chloral
chloral hydrate, meets analytical specification of ph. eur., bp, usp, 99.5-101%
chloral hydrate, crystallized, >=98.0% (t)
cloral hydrate
chloralum
CHEMBL455917
NCGC00159374-04
NCGC00159374-03
AKOS009157238
NCGC00257664-01
dtxsid7020261 ,
tox21_200110
cas-302-17-0
dtxcid70261
tox21_111614
418m5916wg ,
unii-418m5916wg
chloraldural
chloral hydrate [usp:ban:jan]
4-01-00-03143 (beilstein handbook reference)
chloral hydrate [vandf]
chloral hydrate [who-dd]
chloral hydrate [jan]
chloral hydrate [green book]
chloral hydrate [ep monograph]
chloral hydrate [mi]
chloral hydrate [who-ip]
cloral hydrate [mart.]
chloral hydrate [ep impurity]
chloral hydrate [usp monograph]
chloral hydrate [hsdb]
chloral hydrate [iarc]
chlorali hydras [who-ip latin]
chloralum [hpus]
SCHEMBL34327
tox21_111614_1
Q-200826
STL445706
J-520014
F0001-0929
chloral hydrate, saj special grade, >=99.7%
chloral hydrate, saj first grade, >=99.5%
chloral hydrate, p.a., 99.0%
chloralhydrate 1000 microg/ml in acetonitrile
Q412340
chloral hydrate 1000 microg/ml in methanol
2,2,2-trichloroethane-1,1-diol;trichloroacetaldehyde hydrate
BCP31225
chloral hydrate;2,2,2-trichloro-1,1-ethanediol;1,1-ethanediol, 2,2,2-trichloro-;choral hydrate;2,2,2-trichloroethane-1,1-diol;2,2,2trichloroethane1,1diol
trichloroethanal hydrate
A936505
trichloro acetaldehyde hydrate chloral hydrate
chloral hydrate (ep impurity)
chloral hydrate (ep monograph)
cloral hydrate (mart.)
chloral, monohydrate
chloral hydrate (usp monograph)
chloral hydrate (usp:ban:jan)
chloral hydrate (iarc)
chloraldural (swiss)
trichloroethylidene glycol

Research Excerpts

Overview

Chloral hydrate is a sedative-hypnotic drug widely used for relieving fear and anxiety in pediatric patients. It is a common disinfection by-product found in treated water, and its effective control is important to human health.

ExcerptReferenceRelevance
"Chloral hydrate is a commonly used sedative for children."( Nasal drip of dexmedetomidine for optimal sedation during PICC insertion in pediatric burn care.
Gu, L; Li, S; Lu, Y; Peng, C; Wu, Y; Xie, L, 2023
)
1.63
"Chloral hydrate is a sedative-hypnotic drug widely used for relieving fear and anxiety in pediatric patients. "( Trichloroethanol, an active metabolite of chloral hydrate, modulates tetrodotoxin-resistant Na
Jang, IS; Kim, G; Kim, H, 2023
)
2.62
"Chloral hydrate (CH) is a sedative that has been widely used, but its rectal use for child sedation after head trauma has rarely been studied."( Rectal chloral hydrate sedation for computed tomography in young children with head trauma.
Ding, H; Hui, P; Nie, Q; Wang, Z, 2021
)
1.8
"Chloral hydrate (CH) is a common disinfection by-product found in treated water, and its effective control is important to human health. "( Photolysis of chloral hydrate in water with 254 nm ultraviolet: Kinetics, influencing factors, mechanisms, and products.
Chen, B; Gan, Y; Guo, X; Jassby, D; Ma, S, 2019
)
2.32
"Chloral hydrate is a sedative that has been used for many years in clinical practice and, under proper conditions, gives a deep and long enough sleep to allow performance of objective hearing tests in young children. "( Safety and effectiveness of chloral hydrate in outpatient paediatric sedation for objective hearing tests.
Blebea, C; Cozma, S; Necula, V; Stamate, MC, 2019
)
2.25
"Chloral hydrate is a sedative that has been used for magnetic resonance imaging (MRI)."( Chloral hydrate in pediatric magnetic resonance imaging: evaluation of a 10-year sedation experience administered by radiologists.
Angel, GJ; Arango, A; Calvo, V; Delgado, J; Delgado, JA; Rascovsky, S; Toro, R, 2015
)
3.3
"Chloral hydrate is an appropriate sedation option for pediatric patients in MRI services when strict patient selection criteria are met. "( Chloral hydrate in pediatric magnetic resonance imaging: evaluation of a 10-year sedation experience administered by radiologists.
Angel, GJ; Arango, A; Calvo, V; Delgado, J; Delgado, JA; Rascovsky, S; Toro, R, 2015
)
3.3
"Chloral hydrate is a clinical sedative."( Pre-conditioned place preference treatment of chloral hydrate interrupts the rewarding effect of morphine.
Ma, Y; Sun, Y; Wang, J; Zhou, M; Zong, W, 2015
)
1.4
"Chloral hydrate (CH) is a disinfection byproduct commonly found in disinfected water, and once formed, CH may undergo several transformation processes in water distribution system. "( Toward better understanding of chloral hydrate stability in water: Kinetics, pathways, and influencing factors.
Chen, B; Guo, X; Ma, S, 2016
)
2.16
"Chloral hydrate is a clinical anesthetic drug and sedative that has also been reported to attenuate inflammatory response, but the mechanisms are not clearly understood."( Chloral Hydrate Treatment Induced Apoptosis of Macrophages via Fas Signaling Pathway.
Cai, J; Chen, Q; Chen, T; He, Y; Liao, H; Pan, Q; Peng, Y; Wu, P; Xie, T; Zhang, L, 2016
)
2.6
"Chloral Hydrate (CH) is a sedative and hypnotic drug used in pediatric procedures owing to the low depressive effect it has on the respiratory and cardiac systems."( Chloral hydrate to study auditory brainstem response.
Carvalho e Silva, FL; Fávero, ML; Pio, MR; Ponce, FA; Tabith Junior, A,
)
3.02
"Chloral hydrate (CH) is an oral sedative widely used to sedate infants and young children during auditory brainstem response (ABR) testing. "( Use of chloral hydrate as a sedative for auditory brainstem response testing in a pediatric population.
Avlonitou, E; Balatsouras, DG; Douniadakis, D; Giannakopoulos, P; Margaritis, E; Tsakanikos, M, 2011
)
2.27
"Chloral hydrate is a sedative commonly used in pediatric medicine. "( The assessment of genotoxic effects in lymphocyte cultures of infants treated with chloral hydrate.
Dogan, H; Ikbal, M; Ors, R; Pirim, I; Tastekin, A, 2004
)
1.99
"Chloral hydrate is a safe and effective agent for sedation in children with an age and weight dependent response."( Chloral hydrate. An effective agent for sedation in children with age and weight dependent response.
Al-Eissa, YA; Haidar, NA; Hijazi, OM, 2005
)
3.21
"Chloral hydrate is a widely used hypnotic drug for children and animals but the possible interactions of its sedative action and thyroid hormones has not been investigated. "( The effect of chloral hydrate on the in-vitro T3 binding to adult rat cerebral nuclei.
Bolaris, S; Constantinou, C; Margarity, M; Valcana, T, 2005
)
2.13
"Chloral hydrate (CH) is a short-lived intermediate in the metabolism of trichloroethylene (TRI). "( Kinetics of chloral hydrate and its metabolites in male human volunteers.
Bull, RJ; Hu, M; Merdink, JL; Parker, JC; Robison, LM; Stevens, DK, 2008
)
2.17
"Chloral hydrate is a potent non-ionic dissociating agent for cytochrome c oxidase and its use in polyacrylamide-gel electrophoresis, with variation in the pH of the gel, permits charge-dependent separations that should have general application in the analysis of membrane proteins."( Additional components of bovine heart cytochrome c oxidase demonstrated by high-resolution polyacrylamide-gel electrophoresis in the presence of chloral hydrate.
Griffin, DC; Landon, M, 1981
)
1.18
"Chloral hydrate is an oral sedative commonly used in pediatric dentistry when providing extensive treatment in the young child. "( Chloral hydrate sedation: a simple technique.
De Ball, S; Duncan, WK; Perkins, TM, 1994
)
3.17
"Chloral hydrate is a sedative/hypnotic agent that is sometimes administered to patients being treated with cyclophosphamide."( Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.
Maki, PA; Sladek, NE, 1993
)
1.22
"Chloral hydrate is a safe and effective agent for sedation of children with known or suspected congenital heart disease who are undergoing echocardiography in the outpatient cardiology clinic."( Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography.
Ingall, CG; Martin, GR; Napoli, KL, 1996
)
1.33
"Chloral hydrate is a hepatocarcinogen in mice but not rats. "( Metabolism of chloral hydrate in mice and rats after single and multiple doses.
Beland, FA; Fullerton, NF; Schmitt, TC; Young, JF, 1998
)
2.1
"Chloral hydrate is an old psychotropic agent that has never been adequately assessed in the clinical setting. "( Chloral hydrate: a risky old psychotropic drug.
, 1998
)
3.19
"Chloral hydrate (CH) is a commonly found disinfection by-product in water purification, a metabolite of trichloroethylene, and a sedative/hypnotic drug. "( Effect of enterohepatic circulation on the pharmacokinetics of chloral hydrate and its metabolites in F344 rats.
Bull, RJ; Merdink, JL; Parker, JC; Stenner, RD; Stevens, DK, 1999
)
1.99
"Chloral hydrate (CH) is a widely used oral sedative hypnotic drug. "( Chloral hydrate: the good and the bad.
Nichols, M; Palmisano, P; Pershad, J, 1999
)
3.19
"Chloral hydrate (CH) is a widely used sedative. "( Determination of chloral hydrate metabolites in human plasma by gas chromatography-mass spectrometry.
Henderson, GN; James, MO; Stacpoole, PW; Yan, Z, 1999
)
2.09
"Chloral hydrate is a dangerous hypnotic drug to prescribe. "( Chloral hydrate poisoning: its mechanism and therapy.
de Groot, G; Gerretsen, M; Maes, RA; van Heijst, AN, 1979
)
3.15
"Chloral hydrate is a compound of environmental significance. "( Induction of neoplastic lesions in the livers of C57BL x C3HF1 mice by chloral hydrate.
Abrahams, C; Ghose, T; Rao, KV; Rijhsinghani, KS; Swerdlow, MA, 1986
)
1.95

Effects

Chloral hydrate has been used medicinally since the 1800s as a sedative hypnotic, most commonly for procedural sedation. Chloral Hydrate has limited availability in some countries, creating the need for alternative effective sedatives.

ExcerptReferenceRelevance
"Chloral hydrate has been used medicinally since the 1800 s as a sedative hypnotic, most commonly for procedural sedation. "( Pediatric chloral hydrate poisonings and death following outpatient procedural sedation.
Clark, RF; Hardmaslani, M; Nordt, SP; Rangan, C; Valente, M; Wendler, C, 2014
)
2.25
"Chloral hydrate has limited availability in some countries, creating the need for alternative effective sedatives."( Comparison of dexmedetomidine and chloral hydrate sedation for transthoracic echocardiography in infants and toddlers: a randomized clinical trial.
Hossain, M; Kurth, D; Loepke, A; Miller, J; Xue, B; Zhang, MZ, 2016
)
1.43
"Chloral hydrate has been the drug of choice for uncooperative infants and children requiring sedation for echocardiography. "( Efficacy of Reconstituted Oral Chloral Hydrate from Crystals for Echocardiography Sedation.
Frommelt, PC; Hill, GD; Walbergh, DB, 2016
)
2.16
"Chloral hydrate has been one of the sedative drugs most used in children over the last 3 decades, with supporting evidence for its efficacy and safety."( Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate.
Barbi, E; Cozzi, G; Norbedo, S, 2017
)
1.4
"Chloral hydrate medication has to be considered as a cause for false-positive EtG screening results by the DRI EtG immunoassay even in cases with regular chloral hydrate treatment (250-1000 mg) and the more in patients with chloral hydrate tolerance (taking g/day)."( False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC-MS/MS and self-medication.
Arndt, T; Gierten, B; Grüner, J; Güssregen, B; Werle, A, 2009
)
1.31
"Chloral hydrate has been long used as a safe sedative and hypnotic drug in humans. "( Cardiac arrhythmias induced by chloral hydrate in rhesus monkeys.
Han, P; Kang, YJ; Song, H; Xie, H; Yang, P, 2011
)
2.1
"Chloral hydrate has been found in our drinking water supplies at levels up to 5 micrograms/1. "( Humoral and cell-mediated immune status in mice exposed to chloral hydrate.
Borzelleca, JF; Douglas, KA; Kauffmann, BM; Munson, AE; Sain, LE; Sanders, VM; White, KL, 1982
)
1.95
"Chloral hydrate has been found in our drinking water supplies at levels up to 5 micrograms/1. "( Toxicology of chloral hydrate in the mouse.
Barnes, DW; Borzelleca, JF; Bradshaw, TJ; Douglas, KA; Kauffmann, BM; Munson, AE; Sain, LE; Sanders, VM; White, KL, 1982
)
2.07
"Chloral hydrate has been shown to be genotoxic in numerous prokaryotic and eukaryotic assay systems including human lymphocytes in vitro."( NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland, FA, 1999
)
1.26
"Chloral hydrate has been time honored for pediatric procedural sedation, but its efficacy in sedation for emergency department (ED) procedures is unreported. "( Chloral hydrate for emergent pediatric procedural sedation: a new look at an old drug.
Binder, LS; Leake, LA, 1991
)
3.17
"Chloral hydrate (CH) has been assayed for its ability to induce chromosome number variation in human lymphocytes in culture. "( Aneuploidy induced by chloral hydrate detected in human lymphocytes with the Y97 probe.
De Carli, L; De Sario, A; Vagnarelli, P, 1990
)
2.04
"Chloral hydrate has been used extensively to sedate children, but at Brooke Army Medical Center, other drug combinations were becoming increasingly popular due to a perception that chloral hydrate had a high rate of failure, especially with younger or neurologically impaired children. "( Efficacy of sedation of children with chloral hydrate.
Atkinson, SW; Fox, DJ; Rumm, PD; Takao, RT, 1990
)
1.99
"Chloral hydrate has been used clinically for over 100 years. "( Chloral hydrate sedation in neonates and infants--clinical and pharmacologic considerations.
Gorecki, DK; Hindmarsh, KW; Kasian, GF; Reimche, LD; Sankaran, K; Tan, L, 1989
)
3.16

Actions

Chloral hydrate as cause for suspected ADR was classified as probable in 39 events (35.5%) and as possible in 70 (63.6%) Chloral Hydrate did not increase the prevalence of neoplasia at any other organ site.

ExcerptReferenceRelevance
"Chloral hydrate as cause for suspected ADR was classified as probable in 39 events (35.5%) and as possible in 70 (63.6%), and no event was classified as definite."( Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil.
Carvalho, PR; Martinbiancho, JK; Moreira, LB; Rau, R; Schweiger, AP; Trotta, Ede A, 2009
)
1.39
"Chloral hydrate did not increase the prevalence of neoplasia at any other organ site."( Carcinogenicity of chloral hydrate administered in drinking water to the male F344/N rat and male B6C3F1 mouse.
DeAngelo, AB; George, MH; Kilburn, S; Moore, T; Olson, GR,
)
1.18
"The chloral hydrate induced increase in 3H-choline occurred also in animals with chronic septal lesions."( Effects of anesthetics and septal lesions and stimulation on 3H-acetylcholine formation in rat hippocampus.
Atweh, SF; Kuhar, MJ, 1976
)
0.74

Treatment

Chloral hydrate (3 x 10(-3) M) suppressed 2B1/2 mRNA induction following phenobarbital treatment. Kepone alcohol (10(-5) M), which is not a gem-diol, produced less suppression.

ExcerptReferenceRelevance
"In chloral hydrate treatment with/without FSS, expressions of Cu/Zn-SOD, Mn-SOD, and catalase proteins were high compared to only-melatonin treatments."( Combined Fluid Shear Stress and Melatonin Enhances the ERK/Akt/mTOR Signal in Cilia-Less MC3T3-E1 Preosteoblast Cells.
Jeung, EB; Kim, CH; Yoo, YM, 2018
)
0.99
"Treatment with chloral hydrate (3 x 10(-3) M), like Kepone (10(-5) M), suppressed 2B1/2 mRNA induction following phenobarbital (10(-4) M) treatment, while Kepone alcohol (10(-5) M), which is not a gem-diol, produced less suppression."( Regulation of cytochrome P450 2B1/2 mRNAs by Kepone (chlordecone) and potent estrogens in primary cultures of adult rat hepatocytes on Matrigel.
Guzelian, PS; Kocarek, TA; Schuetz, EG, 1994
)
0.63

Toxicity

Chloral hydrate is a safe and efficacious agent for conscious sedation of infants in the PCICU.

ExcerptReferenceRelevance
" On the basis of the mild liver toxicity (histopathological and clinical) observed in males at the highest doses (168 mg/kg-day), the no observed adverse effect level (NOAEL) for oral exposure of rats to chloral hydrate for 90 days is considered to be 96 mg/kg-day (600 mg/L)."( Ninety-day toxicity study of chloral hydrate in the Sprague-Dawley rat.
Daniel, FB; Olson, GR; Page, NP; Robinson, M; Stober, JA, 1992
)
0.76
"Chlorate hydrate is commonly used for neonatal sedation, but blood levels are infrequently monitored, reflecting an underemphasis of acute toxic effects."( Chloral hydrate toxicity in a term infant.
Anyebuno, MA; Rosenfeld, CR, 1991
)
1.72
" Survival time was prolonged in rats treated with the toxic metals by pretreatment with NKK-105."( Effects of diiospropyl-1,3-dithiol-2-ylidene malonate (NKK-105) on acute toxicity of various drugs and heavy metals.
Hosokawa, T; Kitagawa, H; Saito, H; Sakamoto, K; Sugimoto, T; Yanaura, S, 1982
)
0.26
" Repetitive exposure to CHL at levels of about 1/10th and 1/100th the acute LD50 for 14 or 90 days did not produce delayed or persistent behavioral changes."( Behavioral toxicity of chloral in mice: an approach to evaluation.
Balster, RL; Kaempf, GL; Kallman, MJ,
)
0.13
"The purpose of this prospective study was to determine the frequency of adverse events associated with supplemented and unsupplemented chloral hydrate sedation in a select group of children undergoing CT or MR imaging using the revised American Academy of Pediatrics (AAP) monitoring and management guidelines for pediatric sedation."( Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines.
Dolenga, M; Habisohn-Schuck, C; Sukhani, R; Vade, A, 1995
)
1.94
"Use of supplemented and unsupplemented chloral hydrate sedation provides effective and safe sedation in children if the AAP guidelines for patient selection, monitoring, and management are followed."( Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines.
Dolenga, M; Habisohn-Schuck, C; Sukhani, R; Vade, A, 1995
)
2
"In this sample, chloral hydrate was an effective and safe sedative."( Chloral hydrate side effects in young children: causes and management.
Lipshitz, M; Marino, BL; Sanders, ST,
)
1.92
" Adverse reactions to chloral hydrate sedation included hyperactivity (6%), vomiting (4%), and mild respiratory depression (4%)."( High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age.
Adams, RC; Aspinall, CL; Faerber, EN; Greenberg, SB, 1993
)
1
" However, the low rate of adverse reactions makes chloral hydrate a safe drug for sedation of children undergoing MR imaging."( High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age.
Adams, RC; Aspinall, CL; Faerber, EN; Greenberg, SB, 1993
)
0.94
"We examined records of sedations provided by the paediatric anaesthesiology staff for 455 children (ages 1 mo-17 yr) undergoing MRI or CT scans at our institution over a twelve-month period with regard to the monitoring of adverse events: excessive sedation, agitation, vomiting, hypoxaemia, and major airway compromise."( An audit of adverse events in children sedated with chloral hydrate or propofol during imaging studies.
Albarracin, C; Barst, SM; Bienkowski, RS; Lebowitz, P; Merola, C, 1995
)
0.54
" Chloral hydrate is a safe and effective agent for sedation of children with known or suspected congenital heart disease who are undergoing echocardiography in the outpatient cardiology clinic."( Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography.
Ingall, CG; Martin, GR; Napoli, KL, 1996
)
1.51
" Despite concerns about its safety, chloral hydrate remains a frequently used and safe method of pediatric outpatient sedation."( Safe pediatric outpatient sedation: the chloral hydrate debate revisited.
Burton, DM; Malis, DJ, 1997
)
0.84
"Sedation of children can be done in a safe and highly efficacious manner in a hospital radiology department using a structured sedation program modeled after the guidelines of the American Academy of Pediatrics."( Safety and efficacy of sedation in children using a structured sedation program.
Ball, WS; Egelhoff, JC; Koch, BL; Parks, TD, 1997
)
0.3
" The tool captured data regarding demographics, medications used, adequacy of sedation, monitoring, adverse events, and requirement for escalated care."( Adverse events and risk factors associated with the sedation of children by nonanesthesiologists.
Malviya, S; Tait, AR; Voepel-Lewis, T, 1997
)
0.3
" Children with underlying medical conditions and those who are very young are at increased risk of adverse events, which indicates that a greater degree of vigilance may be required in these patients."( Adverse events and risk factors associated with the sedation of children by nonanesthesiologists.
Malviya, S; Tait, AR; Voepel-Lewis, T, 1997
)
0.3
" The frequency of each post-discharge side effect was correlated with other side effects and 12 patient/technical parameters."( A survey of post-discharge side effects of conscious sedation using chloral hydrate in pediatric CT and MR imaging.
Adamson, SD; Berbaum, KS; Kao, SC; Tatman, LH, 1999
)
0.54
"Although sedation-related adverse events in children in the hospital setting have been extensively reported, limited data are available regarding adverse events after discharge home."( Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children.
Malviya, S; Prochaska, G; Tait, AR; Voepel-Lewis, T, 2000
)
0.31
" Demographics, sedative(s) administered, and adverse events including hypoxemia (decrease in SpO(2) by >/=10% of baseline) and sedation events such as inadequate, failed, or excessive sedation, were documented on the institutional quality assurance tool."( Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children.
Malviya, S; Prochaska, G; Tait, AR; Voepel-Lewis, T, 2000
)
0.31
"Intranasal midazolam administered using an atomizer is as safe (as assessed by physiologic parameters) and effective (as assessed by behavior ratings) as oral chloral hydrate/promethazine for conscious sedation of pediatric dental patients."( Comparing the safety, efficacy and recovery of intranasal midazolam vs. oral chloral hydrate and promethazine.
Briskie, DM; Dallman, JA; Ignelzi, MA,
)
0.56
"The authors report on adverse events and sedation outcomes for an oral sedation regimen of chloral hydrate, meperidine and hydroxyzine with 100 percent oxygen, or O2, supplementation."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.53
" The authors analyzed age, sex, weight, methods of drug delivery, waiting time after drug administration, treatment rendered, treatment time, adverse events, sedation outcomes and the number of visits needed to complete treatment using descriptive statistics, chi 2 tests, t test and analysis of variance."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
"Minimal minor adverse events occurred with this sedation regimen."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
"This oral sedation regimen offers reasonable outcomes with minimal adverse events under a strict protocol and use of O2 supplementation."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
" These results indicated that TCE is metabolized in the male reproductive tract, leading to adverse effects that are more severe in the epididymis than in the testis."( Metabolism and toxicity of trichloroethylene in epididymis and testis.
Forkert, PG; Lash, LH; Nadeau, V; Simmonds, A; Tardif, R, 2002
)
0.31
" While multiple exposure is widely acknowledged, arguments are raised that adverse combined effects might not be evoked by mixtures of substances with dissimilar modes of action and being present at only low concentrations."( Mixture toxicity of priority pollutants at no observed effect concentrations (NOECs).
Altenburger, R; Consolaro, F; Gramatica, P; Scholze, M; Walter, H, 2002
)
0.31
"The practice of administering oral contrast material in children before sedation for abdominal CT appears to be safe when using the sedation drugs and protocols in place at our institution."( Is administration of enteric contrast material safe before abdominal CT in children who require sedation? Experience with chloral hydrate and pentobarbital.
Donnelly, LF; Fricke, BL; Ziegler, MA, 2003
)
0.53
" We characterize the fasting status of patients receiving procedural sedation and analgesia in a pediatric ED and assess the relationship between fasting status and adverse events."( Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department.
Agrawal, D; Gupta, R; Krauss, B; Manzi, SF, 2003
)
0.32
" Preprocedural fasting state and adverse events were recorded."( Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department.
Agrawal, D; Gupta, R; Krauss, B; Manzi, SF, 2003
)
0.32
" Seventy-seven adverse events occurred in 68 (6."( Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department.
Agrawal, D; Gupta, R; Krauss, B; Manzi, SF, 2003
)
0.32
" There was no association between preprocedural fasting state and adverse events."( Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department.
Agrawal, D; Gupta, R; Krauss, B; Manzi, SF, 2003
)
0.32
" The purpose of this study was to describe the physiologic responses to chloral hydrate sedation, to report the occurrence of adverse events, and to identify any risk factors that predicted these adverse events in children who underwent sedation for echocardiography at our institution."( Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors.
Coursey, M; Heistein, LC; Lemler, MS; Ramaciotti, C; Scott, WA; Sheeran, PW, 2006
)
2.01
" Vital signs and oxygen saturations were recorded every 5 minutes, and adverse events were noted."( Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors.
Coursey, M; Heistein, LC; Lemler, MS; Ramaciotti, C; Scott, WA; Sheeran, PW, 2006
)
1.78
" Adverse events occurred in 10."( Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors.
Coursey, M; Heistein, LC; Lemler, MS; Ramaciotti, C; Scott, WA; Sheeran, PW, 2006
)
1.78
" The majority of adverse events were minor, and major events were uncommon."( Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors.
Coursey, M; Heistein, LC; Lemler, MS; Ramaciotti, C; Scott, WA; Sheeran, PW, 2006
)
1.78
"To evaluate the utilization of chloral hydrate (CH) for sedation in pediatric intensive care and the incidence of adverse drug reactions."( Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil.
Carvalho, PR; Martinbiancho, JK; Moreira, LB; Rau, R; Schweiger, AP; Trotta, Ede A, 2009
)
0.95
" Data were collected from a spreadsheet for daily monitoring, and clinical events registered in the patient records were analyzed to evaluate the causality of suspected adverse drug reactions (ADR), applying the Naranjo algorithm."( Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil.
Carvalho, PR; Martinbiancho, JK; Moreira, LB; Rau, R; Schweiger, AP; Trotta, Ede A, 2009
)
0.67
" Oxygen desaturation was the most frequent adverse event (64."( Evidence of safety of chloral hydrate for prolonged sedation in PICU in a tertiary teaching hospital in southern Brazil.
Carvalho, PR; Martinbiancho, JK; Moreira, LB; Rau, R; Schweiger, AP; Trotta, Ede A, 2009
)
0.67
" There were no significant adverse events in either cohort."( A comparison of the efficacy and safety of chloral hydrate versus inhaled anesthesia for sedating infants and toddlers for transthoracic echocardiograms.
Calfin, D; Cohen, MS; Jobes, DR; Jones, LA; Montenegro, LM; Nicolson, SC; O'Neill, D, 2010
)
0.62
"To compare the occurrence of post-discharge adverse events in children having received a high dose of either chloral hydrate (CH) or midazolam (MZ) during outpatient dental treatment."( Post-discharge adverse events following pediatric sedation with high doses of oral medication.
Bendo, CB; Brasileiro, SV; Costa, LR; Costa, PS; Paiva, SM; Viegas, CM, 2012
)
0.59
" During treatment, a single observer recorded intraoperative adverse events."( Post-discharge adverse events following pediatric sedation with high doses of oral medication.
Bendo, CB; Brasileiro, SV; Costa, LR; Costa, PS; Paiva, SM; Viegas, CM, 2012
)
0.38
"The most common intraoperative and post-discharge adverse events were hallucination (3."( Post-discharge adverse events following pediatric sedation with high doses of oral medication.
Bendo, CB; Brasileiro, SV; Costa, LR; Costa, PS; Paiva, SM; Viegas, CM, 2012
)
0.38
"High doses of CH were associated with post-discharge adverse events in children having undergone pediatric dental sedation, whereas high doses of MZ were not associated with these events in pediatric patients."( Post-discharge adverse events following pediatric sedation with high doses of oral medication.
Bendo, CB; Brasileiro, SV; Costa, LR; Costa, PS; Paiva, SM; Viegas, CM, 2012
)
0.38
"The goal of this study was to examine childhood overweight/obesity as a risk factor for adverse events during sedation for dental procedures."( The safety of sedation for overweight/obese children in the dental setting.
Anderson, JA; Kang, J; Lee, JY; Vann, WF,
)
0.13
" Of these, 431 (86%) experienced no adverse events, 73 (14%) experienced one or more adverse events, and 6 had missing data."( The safety of sedation for overweight/obese children in the dental setting.
Anderson, JA; Kang, J; Lee, JY; Vann, WF,
)
0.13
"Overall, weight percentiles were higher in children who had one or more adverse events."( The safety of sedation for overweight/obese children in the dental setting.
Anderson, JA; Kang, J; Lee, JY; Vann, WF,
)
0.13
" All demographic data, sedation and procedure duration, sedation success and adverse events were recorded."( Utilisation of an outpatient sedation unit in paediatric ophthalmology: safety and effectiveness of chloral hydrate in 1509 sedation episodes.
Griffiths, B; Mireskandari, K; Shariff, Y; Stephens, D; West, SK, 2013
)
0.61
" Adverse events included paradoxical reaction (1."( Utilisation of an outpatient sedation unit in paediatric ophthalmology: safety and effectiveness of chloral hydrate in 1509 sedation episodes.
Griffiths, B; Mireskandari, K; Shariff, Y; Stephens, D; West, SK, 2013
)
0.61
" Patients over 15 kg and need for a top up dose are risk factors for failure and adverse events."( Utilisation of an outpatient sedation unit in paediatric ophthalmology: safety and effectiveness of chloral hydrate in 1509 sedation episodes.
Griffiths, B; Mireskandari, K; Shariff, Y; Stephens, D; West, SK, 2013
)
0.61
" No major adverse events were documented."( The safety and efficacy of chloral hydrate sedation for pediatric ophthalmic procedures: a retrospective review.
Al Djasim, L; Al Shamrani, M; Edward, DP; Friedman, DS; Karaoui, M; Wilson, ME,
)
0.43
"The use of chloral hydrate sedation for ophthalmic evaluation and imaging was safe and effective in this patient population with a high rate of procedure completion."( The safety and efficacy of chloral hydrate sedation for pediatric ophthalmic procedures: a retrospective review.
Al Djasim, L; Al Shamrani, M; Edward, DP; Friedman, DS; Karaoui, M; Wilson, ME,
)
0.82
"The study investigated patient discharge parameters and postdischarge adverse events after discharge among children who received oral conscious sedation for dental treatment."( Oral Sedation Postdischarge Adverse Events in Pediatric Dental Patients.
Huang, A; Tanbonliong, T, 2015
)
0.42
"To devise a safe and effective sedation protocol for imaging paediatric patients in a small district general hospital (DGH)."( Paediatric sedation for imaging is safe and effective in a district general hospital.
Bailey, MA; Dale, G; Saraswatula, A; Softley, L, 2016
)
0.43
" We retrospectively reviewed case notes for this time period to establish rates of successful sedation and adverse events."( Paediatric sedation for imaging is safe and effective in a district general hospital.
Bailey, MA; Dale, G; Saraswatula, A; Softley, L, 2016
)
0.43
" No serious adverse events were reported."( Paediatric sedation for imaging is safe and effective in a district general hospital.
Bailey, MA; Dale, G; Saraswatula, A; Softley, L, 2016
)
0.43
"This is a safe and effective protocol for delivering sedation for imaging in paediatric patients."( Paediatric sedation for imaging is safe and effective in a district general hospital.
Bailey, MA; Dale, G; Saraswatula, A; Softley, L, 2016
)
0.43
"There are many different sedation protocols in the literature for imaging in paediatric patients, with varying levels of success and adverse event rates."( Paediatric sedation for imaging is safe and effective in a district general hospital.
Bailey, MA; Dale, G; Saraswatula, A; Softley, L, 2016
)
0.43
" We reviewed the dosage of drug used, condition of the child after chloral hydrate administration, adverse effects, audiological results, patients' vital signs, and the effectiveness of the sedative in keeping the child asleep throughout the duration of the test."( Chloral hydrate sedation for auditory brainstem response (ABR) testing in children: Safety and effectiveness.
Atkins, CL; Beers, A; Chadha, NK; Kozak, FK; Kumar, DS; Valenzuela, DG, 2016
)
2.11
" Based on our results, the use of chloral hydrate in the presence of a sedation nurse was a safe and reliable method of performing ABR in infants and children."( Chloral hydrate sedation for auditory brainstem response (ABR) testing in children: Safety and effectiveness.
Atkins, CL; Beers, A; Chadha, NK; Kozak, FK; Kumar, DS; Valenzuela, DG, 2016
)
2.16
" All observed adverse effects were transient and there was no need for resuscitation or use of injectable medications."( Efficacy and safety of chloral hydrate sedation in infants for pulmonary function tests.
Lanza, FC; Nogueira, MC; Solé, D; Wandalsen, GF, 2016
)
0.74
"The data demonstrated that chloral hydrate at the employed doses is a safe and effective medicament for sedation during short procedures in infants, such as pulmonary function tests."( Efficacy and safety of chloral hydrate sedation in infants for pulmonary function tests.
Lanza, FC; Nogueira, MC; Solé, D; Wandalsen, GF, 2016
)
1.04
"Water disinfection treatments result in the formation of disinfection byproducts (DBPs) that have been linked to adverse human health outcomes including higher incidence of bladder and colorectal cancer."( Assessing the genotoxicity of two commonly occurring byproducts of water disinfection: Chloral hydrate and bromal hydrate.
Boudenne, JL; Coulomb, B; De Méo, M; Di Giorgio, C; Manasfi, T, 2017
)
0.68
"Our experience suggests that chloral hydrate is a safe and efficacious agent for conscious sedation of infants in the PCICU."( Safety and efficacy of chloral hydrate for conscious sedation of infants in the pediatric cardiovascular intensive care unit.
Chen, ML; Chen, Q; Su, XY; Tu, XZ; Xu, F; Zhang, JX, 2017
)
1.06
" The commonest reported adverse events (AE) were not serious (eg, paradoxical reaction or transient vomiting) and required no intervention."( Safety and efficacy of chloral hydrate for procedural sedation in paediatric ophthalmology: a systematic review and meta-analysis.
Chalvatzis, NT; Haidich, AB; Lathyris, D; Malamaki, P; Mataftsi, A; Prousali, E; Riga, P, 2017
)
0.77
"Despite the paucity of high quality evidence, the existing literature suggests that the use of CH for procedural sedation in children appears to be an effective alternative to general anaesthesia, and it can be safe when administered in the hospital setting with appropriate monitoring and vigilance for intervention."( Safety and efficacy of chloral hydrate for procedural sedation in paediatric ophthalmology: a systematic review and meta-analysis.
Chalvatzis, NT; Haidich, AB; Lathyris, D; Malamaki, P; Mataftsi, A; Prousali, E; Riga, P, 2017
)
0.77
" Despite CH's traditionally high success rates and relatively low rate of adverse events, there is little data on its safety and efficacy as a sedative for ophthalmic procedures in an Asian population."( Safety and Efficacy of Chloral Hydrate Sedation in Paediatric Sedation for Ophthalmic Procedures.
Chan, AM; Chia, AW; Lim, SH; Loh, HP; Tan, GK, 2017
)
0.77
"Details on chloral hydrate dose administered, sedation achieved, vital signs, and adverse events were recorded."( Chloral Hydrate Administered by a Dedicated Sedation Service Can Be Used Safely and Effectively for Pediatric Ophthalmic Examination.
Al Naji, E; Al Shamrani, M; Ali Aljasim, L; Collins, ME; Craven, ER; Friedman, DS; Hamweyah, K; Karaoui, M; Munoz, B; Varadaraj, V, 2018
)
2.31
" Secondary outcomes were time from sedation to discharge and adverse events, including changes in vital signs following chloral hydrate administration."( Chloral Hydrate Administered by a Dedicated Sedation Service Can Be Used Safely and Effectively for Pediatric Ophthalmic Examination.
Al Naji, E; Al Shamrani, M; Ali Aljasim, L; Collins, ME; Craven, ER; Friedman, DS; Hamweyah, K; Karaoui, M; Munoz, B; Varadaraj, V, 2018
)
2.13
" Our study adds to those that have appeared in recent years, showing that chloral hydrate is an effective and safe substance when is used in proper conditions."( Safety and effectiveness of chloral hydrate in outpatient paediatric sedation for objective hearing tests.
Blebea, C; Cozma, S; Necula, V; Stamate, MC, 2019
)
1.04
" In our study chloral hydrate was effective and had only limited adverse effects."( Safety and effectiveness of chloral hydrate in outpatient paediatric sedation for objective hearing tests.
Blebea, C; Cozma, S; Necula, V; Stamate, MC, 2019
)
1.17
"Intranasal dexmedetomidine was a safe and effective sedative for minor paediatric procedures."( Systematic review and meta-analysis found that intranasal dexmedetomidine was a safe and effective sedative drug during paediatric procedural sedation.
Kallio, M; Peltoniemi, O; Pokka, T; Tervonen, M, 2020
)
0.56
" We characterized the distribution of infant characteristics and evaluated the relationship between drug administration and any adverse event."( Comparative safety profile of chloral hydrate versus other sedatives for procedural sedation in hospitalized infants.
Balevic, S; Chu, V; Clark, R; Crenshaw, EG; Dallefeld, SH; Daniel, KR; Gilleskie, ML; Greenberg, RG; Kumar, KR; Smith, DS; Smith, PB; Zimmerman, KO, 2020
)
0.85
" Adverse events occurred in 41 (6%) infants."( Comparative safety profile of chloral hydrate versus other sedatives for procedural sedation in hospitalized infants.
Balevic, S; Chu, V; Clark, R; Crenshaw, EG; Dallefeld, SH; Daniel, KR; Gilleskie, ML; Greenberg, RG; Kumar, KR; Smith, DS; Smith, PB; Zimmerman, KO, 2020
)
0.85
"Administration of chloral hydrate to hospitalized infants undergoing minor procedures is associated with a lower risk for adverse events compared to other sedatives."( Comparative safety profile of chloral hydrate versus other sedatives for procedural sedation in hospitalized infants.
Balevic, S; Chu, V; Clark, R; Crenshaw, EG; Dallefeld, SH; Daniel, KR; Gilleskie, ML; Greenberg, RG; Kumar, KR; Smith, DS; Smith, PB; Zimmerman, KO, 2020
)
1.18
" Analysis of sedation success/failure rates, sleep induction time (SIT), sleep duration time (SDT), and adverse events (AE), was performed."( The safety and efficacy of a nurse-led sedation service using Chloral Hydrate for auditory brainstem response testing.
Berkenstadt, H; Henkin, Y; Many, YA,
)
0.37
"Findings support the use of a structured PNLSP using CH as safe and efficient."( The safety and efficacy of a nurse-led sedation service using Chloral Hydrate for auditory brainstem response testing.
Berkenstadt, H; Henkin, Y; Many, YA,
)
0.37
" Compared with oral CH, intranasal dexmedetomidine significantly decreased the incidence of adverse events, including vomiting, but increased the incidence of bradycardia."( Efficacy and safety of intranasal dexmedetomidine versus oral chloral hydrate as sedatives for pediatric patients: a systematic review and meta-analysis.
Huang, C; Li, N; Li, Y; Shi, B; Tang, W; Wang, J; Xia, Z; Xiao, S; Xu, H, 2022
)
0.96
" Although efforts are made to prevent adverse events, no sedation protocol has specified the optimal regimen, dosage, and interval of medication to prevent adverse events."( Safety and efficacy of pediatric sedation protocol for diagnostic examination in a pediatric emergency room: A retrospective study.
Choi, SJ; Chun, MK; Kim, DH; Lee, JS; Lee, JY; Park, JS; Ryu, JM, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The pre- and post-plasma half-life values were 35 hours, while on dialysis the half-life was only 6 hours."( Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis.
Benet, LZ; Fukumitsu, CJ; Gambertoglio, JG; Naughton, JL; Stalker, NE,
)
0.49
" Pharmacokinetic parameters and enzyme kinetic data both in normal and in tumor-bearing animals will be presented."( Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
Bartosek, I; Colombo, T; Donelli, MG; Guaitani, A; Martini, A; Modica, R; Pacciarini, MA, 1976
)
0.26
" After termination of treatment the half-life of TCE was 12."( Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion.
Buur, T; Larsson, R; Norlander, B, 1988
)
0.6
" After intravenous administration, CH rapidly disappeared from blood with a terminal half-life ranging from 5 to 24 min."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.59
"A six-compartment physiologically based pharmacokinetic (PBPK) model for the B6C3F1 mouse was developed for trichloroethylene (TCE) and was linked with five metabolite submodels consisting of four compartments each."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.52
" Due to the extremely short terminal half-life of chloral hydrate its active metabolite trichloroethanol is regarded as the pharmacokinetically relevant parameter for the assessment of the bioavailability of the parent substance."( [The relative bioavailability and pharmacokinetics of chloral hydrate and its metabolites].
Schulz, HU; Wehling, M; Zimmermann, T, 1998
)
0.8
"A physiologically based pharmacokinetic (PBPK) model for inhaled trichloroethylene (TCE) was developed for B6C3F1 mice."( Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice.
Burton, GA; Fisher, JW; Greenberg, MS, 1999
)
0.3
"Bayesian population analysis of a harmonized physiologically based pharmacokinetic (PBPK) model for trichloroethylene (TCE) and its metabolites was performed."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"The purpose of this study was to compare the effectiveness of a chloral hydrate/hydroxyzine combination with and without meperidine in the sedation of pediatric dental patients."( Comparison of a chloral hydrate/hydroxyzine combination with and without meperidine in the sedation of pediatric dental patients.
Farrington, FH; Mourino, AP; Poorman, TL,
)
0.72

Bioavailability

Two open, randomized cross-over trials were performed in 18 healthy volunteers each to evaluate the relative bioavailability and the pharmacokinetics of chloral hydrate (CAS 302-17-0) The plasma levels of TaClo were determined at various time-points.

ExcerptReferenceRelevance
"Given the high bioavailability of oral chloral hydrate the major determinant of cardiotoxicity may be the dose rather than the route of administration."( Chloral hydrate toxicity from oral and intravenous administration.
Amitai, Y; Erickson, T; Hryhorczuk, D; Sing, K, 1996
)
2.01
"22 GHz with a peak specific absorption rate of 420 W/kg and corresponding incident power density of 15 mW/cm2 for 15 min or sham-exposed."( Electromagnetic millimeter waves increase the duration of anaesthesia caused by ketamine and chloral hydrate in mice.
Rojavin, MA; Ziskin, MC, 1997
)
0.52
" Hence, the plasma levels of TaClo were determined at various time-points in 18 healthy volunteers in two periods each during a bioavailability study of several chloral hydrate preparations."( [The plasma level of the neurotoxin 1-trichloromethyl-1,2,4,5-tetrahydro-beta-carboline (TaClo) in man after oral administration of chloral hydrate].
Beuscher, N; Jeromin, J; Leuschner, J; Ritter, H; Schulz, HU; Schürer, M; Zimmermann, T, 1998
)
0.7
"Two open, randomized cross-over trials were performed in 18 healthy volunteers each to evaluate the relative bioavailability and the pharmacokinetics of chloral hydrate (CAS 302-17-0), the active ingredient of Chloraldurat 500 (immediate release capsules, CH), Chloraldurat rot (immediate release capsules, CR) and Chloraldurat blau (enteric-coated modified release capsules, CB)."( [The relative bioavailability and pharmacokinetics of chloral hydrate and its metabolites].
Schulz, HU; Wehling, M; Zimmermann, T, 1998
)
0.75
"For lack of clinical safety data, preclinical tests for cutaneous cytotoxicity and calculations for systemic bioavailability after topical application have been performed."( [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
Fischer, M; Gilbrich, F; Philipp, S; Wohlrab, J; Wolff, L, 2017
)
0.73
" For a better assessment of harmlessness, tests for cutaneous bioavailability (concentration-time profile) on human skin and clinical studies would be necessary."( [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
Fischer, M; Gilbrich, F; Philipp, S; Wohlrab, J; Wolff, L, 2017
)
0.73
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Chloral hydrate is a repetitive dosing sedative. There was no evidence of a dose-response relationship between chloral Hydrate and risk of any of the other four cancers. Health-care professionals caring for hospitalised infants should be made aware of the potential risks.

ExcerptRelevanceReference
" Possibly, morphine has a diphasic dose-response curve with respect to cardiovascular function and, by inference, on brain noradrenergic mechanisms."( Effects of morphine on central catecholamine turnover, blood pressure and heart rate in the rat.
Gomes, C; Svensson, TH; Trolin, G, 1976
)
0.26
" The method has been used to determine plasma levels after therapeutic dosing with chloral preparations."( Determination of trichloroethanol at therapeutic and overdose levels in blood and urine by electron capture gas chromatography.
Berry, DJ, 1975
)
0.25
" Both At and Sc in a wide range of dosage protect against the tonic phase of convulsions produced by electroshock."( Central action of drugs acting on the cholinergic muscarinic receptor. III. Influence of atropine and scopolamine injected intraventricularly on behavior and levels of biogenic amines in the rat brain.
Kleinrok, Z; Poddubiuk, Z; Zebrowska-Lupina, I, 1975
)
0.25
" In further in vivo voltammetric studies, the effects of SC cocaine on synaptic concentrations of DA and 5-HT were studied in the chloral hydrate-anesthetized paradigm in two neuroanatomic substrates, NAcc and mesoaccumbens somatodendrites, the ventral tegmental area (VTA-A10), in a dose-response fashion (10, 20, and 40 mg/kg) in six separate studies."( Distinguishing effects of cocaine i.v. and SC on mesoaccumbens dopamineand serotonin release with chloral hydrate anesthesia.
Broderick, PA, 1992
)
0.71
"This study evaluated the dose-response effect of chloral hydrate (CH) used alone on several physiological parameters in 26 healthy children 21 to 42 months old."( Chloral hydrate and its effects on multiple physiological parameters in young children: a dose-response study.
Wilson, S,
)
1.83
" Chloral hydrate in dosages of 25 mg/kg to 100 mg/kg is the most common drug used for sedation; DPT, a combination of parenteral Demerol (meperidine), Phenergan (promethazine), and Thorazine (chlorpromazine), at a maximum dose of 2 mg/1 mg/1 mg/kg is the second; and pentobarbital in a dosage of 5 mg/kg to 7 mg/kg is the third."( Sedation of children for technical procedures: current standard of practice.
Alexander, ME; Bass, JW; Cook, BA; Nomizu, S, 1992
)
1.19
" The present study investigated the nature of desaturations in relation to patient activity as a function of a drug combination, single drug dose-response design, and placebo conditions."( Conscious sedation and pulse oximetry: false alarms?
Wilson, S,
)
0.13
"Eighty-six patients with acute psychotic exacerbations were treated with fixed dosage regimens of oral fluphenazine up to 10-30 mg/day in randomized, double-blind studies."( Acute dystonia during fixed-dose neuroleptic treatment.
Friedman, E; Levinson, DF; Lo, ES; Simpson, GM; Singh, H, 1990
)
0.28
" The minimum dosage of CH to produce ulcers was 400 mg/kg intraperitoneally and 600 mg/kg subcutaneously."( Gastric mucosal injury induced by chloral hydrate.
Hobara, T; Iwamoto, S; Kobayashi, H; Ogino, K, 1990
)
0.56
" It is concluded that when a healthy child receives a sedative agent for dental treatment, the type of drug and drug dosage depend more on the biases of the individual practitioner, than on the requirements of the patient."( Report of project USAP: the use of sedative agents in pediatric dentistry.
Houpt, M,
)
0.13
" Subsequent challenge with haloperidol indicated a significant decrease in responsiveness to haloperidol-induced release of DA, but not HVA, in chronically dosed rats."( Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge.
Hong, JS; Stachowiak, MK; Tilson, H; Zhang, W, 1989
)
0.28
" Multiple dosing of chloral hydrate in preterm infants should be used with caution and frequent monitoring of serum bilirubin concentrations is indicated in such cases."( Chloral hydrate sedation in neonates and infants--clinical and pharmacologic considerations.
Gorecki, DK; Hindmarsh, KW; Kasian, GF; Reimche, LD; Sankaran, K; Tan, L, 1989
)
2.04
" Recommendations are made concerning patient supervision, dosage limitations, and degree of sedation."( Death after chloral hydrate sedation: report of case.
Jastak, JT; Pallasch, T, 1988
)
0.65
" The commonly used dose range exceeds the maximum recommended dose; however, the effects of this dosage regimen during pulmonary function testing have not been studied."( Effect of chloral hydrate on arterial oxygen saturation in wheezy infants.
Mallol, J; Sly, PD, 1988
)
0.68
" Intravenous supplementation of the sedation was limited by the protocol to a maximum secobarbital dosage of 2 mg/kg."( The choice of sedation for computed tomography in children: a prospective evaluation.
Ashwal, S; Hasso, AN; Hinshaw, DB; Holden, BS; Schneider, S; Thompson, JR, 1982
)
0.26
" The compound was delivered via the drinking water; levels of the compound delivered per day were equivalent to those dosed in the 14-day study."( Toxicology of chloral hydrate in the mouse.
Barnes, DW; Borzelleca, JF; Bradshaw, TJ; Douglas, KA; Kauffmann, BM; Munson, AE; Sain, LE; Sanders, VM; White, KL, 1982
)
0.62
"The dose-response relationship for carcinogenesis of chloral hydrate and other chemicals in its metabolic breakdown pathway is nonlinear in rodents: very high doses given chronically, sufficient to cause cellular necrosis, are necessary for induction of malignancies."( Should chloral hydrate be banned?
Steinberg, AD, 1993
)
0.99
" The median dosage of chloral hydrate given was 77 mg/kg, with a range of 25 to 125 mg/kg."( Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography.
Ingall, CG; Martin, GR; Napoli, KL, 1996
)
0.92
" Mice were dosed with 67."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.59
" There was no statistical difference as to the mean dosage of diazepam or chloral hydrate between the patients with and without recurrence."( [Efficacy of rectal diazepam suppository in the prophylaxis of febrile seizures: comparison with rectal chloral hydrate suppository].
Kuremoto, K; Oyama, S; Shimazaki, S, 1997
)
0.74
" For oral bolus dosing of TCE with 300, 600, and 2000 mg/kg, model predictions of TCE and several metabolites were in general agreement with observations."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.52
" Male B6C3F1 mice were dosed with TRI, CH, trichloroethanol (TCE), or TCA and metabolic profiles of each were determined."( The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice.
Bull, RJ; Gonzalez-Leon, A; Merdink, JL; Schultz, IR, 1998
)
0.54
" Supplemental dosing was administered to children who were judged inadequately sedated 30 minutes after the initial medication."( Chloral hydrate versus midazolam for sedation of children for neuroimaging: a randomized clinical trial.
D'Agostino, J; Terndrup, TE, 2000
)
1.75
" Adverse events occurred despite drugs being administered within acceptable dosing limits."( Adverse sedation events in pediatrics: analysis of medications used for sedation.
Coté, CJ; Karl, HW; McCloskey, C; Notterman, DA; Weinberg, JA, 2000
)
0.31
" The median dosage of CH given was 75 mg/kg (ranging 50 and 100 mg), with either oral or rectal administration."( Chloralhydrate in children undergoing echocardiography.
Coskun, S; Onag, A; Yuksel, H, 2001
)
0.31
" Two 800 mg/kg female rats died after dosing ended but before study termination."( NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland, FA, 1999
)
0.54
" One goal of the study was to assess the effect of the animal’s age and the duration of dosing on the tumorigenicity of chloral hydrate."( NTP Technical Report on the Toxicology and Carcinogenesis Studies of Chloral Hydrate (Cas No. 302-17-0) in B6C3F1 mice (Gavage Studies).
, 2002
)
0.76
" Additional male mice were dosed as described above and their livers were excised at 24, 48 h, and 7 days after the final dose."( Tumorigenicity of chloral hydrate, trichloroacetic acid, trichloroethanol, malondialdehyde, 4-hydroxy-2-nonenal, crotonaldehyde, and acrolein in the B6C3F(1) neonatal mouse.
Bucci, TJ; Chou, MW; Fu, PP; Kadlubar, FF; Samokyszyn, VM; Von Tungeln, LS; Yi, P, 2002
)
0.65
"Survival of dosed groups of ad libitum-fed and dietary-controlled mice was similar to that of the corresponding vehicle controls."( Toxicology and carcinogenesis study of chloral hydrate (ad libitum and dietary controlled) (CAS no. 302-17-0) in male B6C3F1 mice (gavage study).
, 2002
)
0.58
"Chloral hydrate did not significantly induce either lauric acid 4-hydroxylase activity or CYP4A immunoreactive protein in any of the dosed groups of ad libitum-fed mice."( Toxicology and carcinogenesis study of chloral hydrate (ad libitum and dietary controlled) (CAS no. 302-17-0) in male B6C3F1 mice (gavage study).
, 2002
)
2.03
" The liver weights of all dosed groups of ad libitum-fed and dietary-controlled mice were greater than those of the vehicle control groups at 2 years, but the increases were not statistically significant."( Toxicology and carcinogenesis study of chloral hydrate (ad libitum and dietary controlled) (CAS no. 302-17-0) in male B6C3F1 mice (gavage study).
, 2002
)
0.58
" Mice were dosed with chloral hydrate at 0, 50, 100, 250, 500, and 1000 mg/kg daily, 5 days/week, by aqueous gavage for 2 weekly dosing cycles."( Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure.
Agrawal, N; Allaben, WT; Horsley, ET; Leakey, JE; Leakey, TI; Scherer, EM; Seng, JE; Xia, S, 2003
)
0.97
" Collected data included demographics, indication, drug dosing and outcome."( Chloral hydrate. An effective agent for sedation in children with age and weight dependent response.
Al-Eissa, YA; Haidar, NA; Hijazi, OM, 2005
)
1.77
" In this analysis, these associations were investigated using: (i) a dose-response analysis among exposed subjects; and (ii) a two-stage design with exposed and non-exposed persons."( Short-term chloral hydrate administration and cancer in humans.
Friedman, GD; Haselkorn, T; Udaltsova, N; Whittemore, AS, 2006
)
0.72
" There was no evidence of a dose-response relationship between chloral hydrate and risk of any of the other four cancers."( Short-term chloral hydrate administration and cancer in humans.
Friedman, GD; Haselkorn, T; Udaltsova, N; Whittemore, AS, 2006
)
0.96
" Strict attention should be paid to the dosing and administration protocol of chloral hydrate in infants."( Severe esophageal burn following chloral hydrate overdose in an infant.
Lin, YC; Ma, JY, 2006
)
0.84
" This analysis provides an important step toward estimating uncertainty of dose-response relationships in noncancer and cancer risk assessment, improving the extrapolation of toxic TCE doses from experimental animals to humans."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33
" In addition, a traditional up-and-down dosing procedure was applied to define a single dose level at which cardiac arrhythmias can be induced."( Cardiac arrhythmias induced by chloral hydrate in rhesus monkeys.
Han, P; Kang, YJ; Song, H; Xie, H; Yang, P, 2011
)
0.66
" Trials were grouped into placebo-controlled, dosage and head-to-head comparisons."( Sedation of children undergoing dental treatment.
Ashley, PF; Furness, S; Lourenço-Matharu, L, 2012
)
0.38
"Chloral hydrate is generally considered a safe and effective single dosing procedural sedative for neonates in the clinical setting."( Prospective clinical audit of chloral hydrate administration practices in a neonatal unit.
Cruise, S; Harrison, D; Johnston, L; Tam-Chan, D, 2012
)
2.11
" Doses were more likely to be given at night than during the day, and the median dosage for repetitive dosing was found to be above the study site's recommended dosing range."( Prospective clinical audit of chloral hydrate administration practices in a neonatal unit.
Cruise, S; Harrison, D; Johnston, L; Tam-Chan, D, 2012
)
0.67
"Health-care professionals caring for hospitalised infants should be made aware of the potential risks of chloral hydrate as a repetitive dosing sedative, and of the importance of systematically evaluating the appropriateness and effectiveness of utilising such pharmacological intervention for managing and treating distress."( Prospective clinical audit of chloral hydrate administration practices in a neonatal unit.
Cruise, S; Harrison, D; Johnston, L; Tam-Chan, D, 2012
)
0.88
"We have established an intraperitoneal dosing regimen for 2,2,2-tribromoethanol-chloral hydrate anesthesia."( Increased anesthesia time using 2,2,2-tribromoethanol-chloral hydrate with low impact on mouse psychoacoustics.
Gow, A; Maheras, KJ, 2013
)
0.87
" Mean cumulative dosage of ch was 643."( Treatment of neonatal abstinence syndrome in preterm and term infants.
Dabek, MT; Englert, S; Poeschl, J; Ruef, P, 2013
)
0.39
"4 μg/mL), metabolized from CH, was measured on the fifth day of the 1 g/day CH dosage but was undetectable in plasma at environmentally relevant doses."( Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans.
Coats, BS; Langaee, T; Shroads, AL; Shuster, JJ; Stacpoole, PW, 2015
)
1.86
" Group C: second oral dose chloral hydrate 25 mg · kg(-1); Group L and Group H: intranasal dexmedetomidine in a dosage of 1 and 2 mcg · kg(-1), respectively."( Comparison of rescue techniques for failed chloral hydrate sedation for magnetic resonance imaging scans--additional chloral hydrate vs intranasal dexmedetomidine.
Fan, Y; Li, B; Song, X; Tian, H; Wang, Z; Zhang, W, 2016
)
0.99
" We reviewed the dosage of drug used, condition of the child after chloral hydrate administration, adverse effects, audiological results, patients' vital signs, and the effectiveness of the sedative in keeping the child asleep throughout the duration of the test."( Chloral hydrate sedation for auditory brainstem response (ABR) testing in children: Safety and effectiveness.
Atkins, CL; Beers, A; Chadha, NK; Kozak, FK; Kumar, DS; Valenzuela, DG, 2016
)
2.11
" There was also no clear evidence for people in one dosage group being more likely to leave the study early, over the other dosage group (moderate-quality evidence)."( Chlorpromazine dose for people with schizophrenia.
De Haan, S; Dudley, K; Liu, X, 2017
)
0.46
"The dosage of chlorpromazine has changed drastically over the past 50 years with lower doses now being the preferred of choice."( Chlorpromazine dose for people with schizophrenia.
De Haan, S; Dudley, K; Liu, X, 2017
)
0.46
" In addition, the initial CH dosage also played an important role, with higher CH being degraded more slowly."( Photolysis of chloral hydrate in water with 254 nm ultraviolet: Kinetics, influencing factors, mechanisms, and products.
Chen, B; Gan, Y; Guo, X; Jassby, D; Ma, S, 2019
)
0.87
" Studies were grouped into placebo-controlled, dosage and head-to-head comparisons."( Sedation of children undergoing dental treatment.
Ashley, PF; Chaudhary, M; Lourenço-Matharu, L, 2018
)
0.48
" This new method can be applied for the pharmacokinetic analysis of TCS and its metabolites and the determination of the optimal TCS dosage in children."( Simple method to detect triclofos and its metabolites in plasma of children by combined use of liquid chromatography tandem-mass spectrometry and gas chromatography-mass spectrometry.
Hashimoto, S; Inoue, M; Ito, Y; Kamijima, M; Nakahira, Y; Nakajima, T; Sato, H, 2019
)
0.51
"This retrospective study compares the efficacy and safety of variable dosing of Chloral Hydrate - Hydroxyzine with and without Meperidine (Mep)for managing varying levels of anxiety and uncooperative behavior of young pediatric dental patients over a 35-year period."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
1.23
"Reviews of the sedation logs of 2,610 children, 3-7 years were compared in search of what dosing proves safe and effective for differing levels of challenging behavior."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
1
"Where Mep was used, success rates were consistently higher; need for higher-end dosing of CH was not found beneficial when Mep was included."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
1
"There appears to be strong basis for the safety and efficacy of the use of CH-H-Mep in combination at lower dosing than historically used."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
1
" Previous studies have confirmed the safety and effectiveness of intravenous/oral dosing or nasal dripping for sedation during the examinations of electrocardiography and computed tomography."( Nasal drip of dexmedetomidine for optimal sedation during PICC insertion in pediatric burn care.
Gu, L; Li, S; Lu, Y; Peng, C; Wu, Y; Xie, L, 2023
)
0.91
"622) and dosage (P = ."( Safety and efficacy of pediatric sedation protocol for diagnostic examination in a pediatric emergency room: A retrospective study.
Choi, SJ; Chun, MK; Kim, DH; Lee, JS; Lee, JY; Park, JS; Ryu, JM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
general anaestheticSubstance that produces loss of consciousness.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ethanediolAny diol that is ethane or substituted ethane carrying two hydroxy groups.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
aldehyde hydrateA 1,1-diol resulting from the formal addition of water to the carbonyl group of a aldehyde.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
superpathway of pyrimidine deoxyribonucleosides degradation738
superpathway of purine deoxyribonucleosides degradation637
2'-deoxy-u03B1-D-ribose 1-phosphate degradation428

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.39140.000214.376460.0339AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.79970.000817.505159.3239AID1159531
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency11.88230.001024.504861.6448AID743215
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.00260.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,814)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901054 (58.10)18.7374
1990's305 (16.81)18.2507
2000's214 (11.80)29.6817
2010's181 (9.98)24.3611
2020's60 (3.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.49 (24.57)
Research Supply Index7.71 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index144.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (79.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials146 (6.98%)5.53%
Reviews88 (4.21%)6.00%
Case Studies126 (6.03%)4.05%
Observational2 (0.10%)0.25%
Other1,729 (82.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children: a Randomized Controlled Trial [NCT04820205]136 participants (Anticipated)Interventional2021-09-03Recruiting
[NCT01149226]100 participants (Actual)Interventional2010-05-31Completed
The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children [NCT02195661]Phase 3194 participants (Actual)Interventional2014-04-30Completed
A Qualitative Comparison of Oral Chloral Hydrate vs 2.0 or 3.0 mcg/kg Nasal Dexmedetomidine in Children Undergoing Transthoracic Echocardiography [NCT02523144]Phase 4279 participants (Actual)Interventional2014-09-30Completed
Evaluation of the Effect of Chloral Hydrate, Hydroxyzine and Melatonin Used as Sedative Drugs in EEG Recording in Children [NCT05492812]180 participants (Actual)Interventional2021-01-01Completed
Sedation to Electroencephalography With Dexmedetomidine or Chloral Hydrate: a Comparative Study of the Qualitative and Quantitative Electroencephalogram Pattern [NCT01083797]Phase 325 participants (Actual)Interventional2009-12-31Completed
[NCT02239445]Phase 4158 participants (Actual)Interventional2014-09-30Completed
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation: a Randomized Controlled Trial [NCT04822064]70 participants (Anticipated)Interventional2022-09-22Recruiting
Use of Chloral Hydrate to Perform Auditory Brainstem Response (ABR) [NCT00949780]Phase 241 participants (Actual)Interventional2007-10-31Completed
Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial [NCT01402596]Phase 20 participants (Actual)Interventional2011-08-31Withdrawn(stopped due to Institution decided on starting a new protocol of sedation, with another methods and that´s why this study has not started.)
A RANDOMIZED CONTROLLED TRIAL OF ORAL CHLORAL HYDRATE VERSUS INTRANASAL DEXMEDETOMIDINE FOR SEDATED ABR EXAMS. [NCT01255904]Phase 490 participants (Actual)Interventional2011-08-31Completed
Prospective, Double Blinded,Randomized Controlled Trial of Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG [NCT00464451]Phase 20 participants (Actual)Interventional2009-08-31Withdrawn(stopped due to Unable to obtain approval from FDA for use of chloral hydrate)
An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia [NCT06053840]Phase 4100 participants (Anticipated)Interventional2023-09-21Recruiting
Pharmacotoxicology of Trichloroethylene Metabolites Aim 3 [NCT01128270]Phase 1/Phase 227 participants (Actual)Interventional2010-04-30Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Effects Comparison Between Oral and Enema of Chloral Hydrate in Pediatric Ophthalmic Examination [NCT03242629]120 participants (Actual)Interventional2017-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01128270 (4) [back to overview]Detectable DCA After Day 1 in Serum (0=No 1=Yes)
NCT01128270 (4) [back to overview]Difference in Half Lives 5 Day Less One Day Exposure in Trichloroacetate
NCT01128270 (4) [back to overview]Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A.
NCT01128270 (4) [back to overview]Urinary Maleylacetone Levels After 5 Day Exposure to Therapeutic Chloral Hydrate (Arm 2B)
NCT01255904 (1) [back to overview]Time to Complete Study

Detectable DCA After Day 1 in Serum (0=No 1=Yes)

All four arms receive Chloral Hydrate on Day 1 (arms 1A and 1B environmental levels) and (arms 2A and 2B therapeutic levels). The question is could Dichloroacetate be detected in serum at the end of day 1. This analysis is purely descriptive, and no comparisons were planned. (NCT01128270)
Timeframe: 1 day

Interventionparticipants (Number)
Environmental Chloral Hydrate and DCA (1A)0
Environmental Chloral Hydrate (1B)0
Therapeutic Chloral Hydrate and DCA (2A)0
Therapeutic Chloral Hydrate (2B)0

[back to top]

Difference in Half Lives 5 Day Less One Day Exposure in Trichloroacetate

Elimination Half-life Difference on Arm 2B for 13C-Labeled trichloroacetate between day 5 (prolonged exposure) and day 1 (de novo exposure) after therapeutic level exposure to Chloral Hydrate. This outcome only applies to Period 4. Trichloroacetate is a marker, not an intervention. (NCT01128270)
Timeframe: 5 days

Interventionminutes (Mean)
Therapeutic Chloral Hydrate (2B)2432

[back to top]

Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A.

After 5 days of of therapeutic level Chloral Hydrate, the levels of Dichloroacetate in the plasma were measured. (NCT01128270)
Timeframe: 6 Days

Interventionmicrograms/ml (Mean)
Therapeutic Chloral Hydrate and DCA (2A)1.64

[back to top]

Urinary Maleylacetone Levels After 5 Day Exposure to Therapeutic Chloral Hydrate (Arm 2B)

The levels were clinically indetectable at baseline and the question was whether or not substantive levels would be noted at after 5 days exposure to Chloral Hydrate. Detectable, but low levels were detected. (NCT01128270)
Timeframe: 5 days

Interventionmicrograms per ml clorohydrate (Mean)
Therapeutic Chloral Hydrate (2B)0.38

[back to top]

Time to Complete Study

Time from medication administration to study completion. (NCT01255904)
Timeframe: 60-180 minutes

InterventionMinutes (Median)
Oral Placebo and Intransal Dexmedetomidine85.5
Oral Chloral Hydrate and Intranasal Placebo110

[back to top]